Top

Published in:

01-06-2010 | PRECLINICAL STUDIES

The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy

Authors: K. Dredge, E. Hammond, K. Davis, C. P. Li, L. Liu, K. Johnstone, P. Handley, N. Wimmer, T. J. Gonda, A. Gautam, V. Ferro, I. Bytheway

Published in: Investigational New Drugs | Issue 3/2010

Summary

Heparan sulfate mimetics, which we have called the PG500 series, have been developed to target the inhibition of both angiogenesis and heparanase activity. This series extends the technology underpinning PI-88, a mixture of highly sulfated oligosaccharides which reached Phase III clinical development for hepatocellular carcinoma. Advances in the chemistry of the PG500 series provide numerous advantages over PI-88. These new compounds are fully sulfated, single entity oligosaccharides attached to a lipophilic moiety, which have been optimized for drug development. The rational design of these compounds has led to vast improvements in potency compared to PI-88, based on in vitro angiogenesis assays and in vivo tumor models. Based on these and other data, PG545 has been selected as the lead clinical candidate for oncology and is currently undergoing formal preclinical development as a novel treatment for advanced cancer.

Available only for authorised users

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257. doi:10.1038/35025220 CrossRefPubMed

Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410. doi:10.1038/nrc1093 CrossRefPubMed

Herbst RS (2006) Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 11:635–650. doi:10.1517/14728214.11.4.635 CrossRefPubMed

Sasisekharan R, Shriver Z, Venkataraman G et al (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521–528. doi:10.1038/nrc842 CrossRefPubMed

Wegrowski Y, Maquart FX (2004) Involvement of stromal proteoglycans in tumour progression. Crit Rev Oncol Hematol 49:259–268. doi:10.1016/j.critrevonc.2003.10.005 CrossRefPubMed

Lever R, Page CP (2002) Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140–148. doi:10.1038/nrd724 CrossRefPubMed

Presta M, Leali D, Stabile H et al (2003) Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 9:553–566. doi:10.2174/1381612033391379 CrossRefPubMed

Karoli T, Liu L, Fairweather JK et al (2005) Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 48:8229–8236. doi:10.1021/jm050618p CrossRefPubMed

Zetser A, Bashenko Y, Edovitsky E et al (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66:1455–1463. doi:10.1158/0008-5472.CAN-05-1811 CrossRefPubMed

10.

Cohen-Kaplan V, Naroditsky I, Zetser A et al (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123:2566–2573. doi:10.1002/ijc.23898 CrossRefPubMed

11.

Vlodavsky I, Elkin M, Abboud-Jarrous G et al (2008) Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 49:207–210. doi:10.1080/03008200802143281 CrossRefPubMed

12.

Cochran S, Li C, Fairweather JK et al (2003) Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 46:4601–4608. doi:10.1021/jm030180y CrossRefPubMed

13.

Cochran S, Li CP, Ferro V (2008). A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconjuate J. doi:10.1007/s10719-008-9210-0

14.

Bisio A, Mantegazza A, Urso E et al (2007) High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase. Semin Thromb Hemost 33:488–495. doi:10.1055/s-2007-982079 CrossRefPubMed

15.

McKenzie E, Young K, Hircock M et al (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373:423–435. doi:10.1042/BJ20030318 CrossRefPubMed

16.

Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108. doi:10.1016/0006-2952(73)90196-2 CrossRefPubMed

17.

Nicosia RF, Ottinetti A (1990) Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26:119–128. doi:10.1007/BF02624102 CrossRefPubMed

18.

Min J-K, Han K-Y, Kim E-C et al (2004) Capsaicin Inhibits in Vitro and in Vivo Angiogenesis. Cancer Res 64:644–651. doi:10.1158/0008-5472.CAN-03-3250 CrossRefPubMed

19.

Auerbach R, Lewis R, Shinners B et al (2003) Angiogenesis assays: a critical overview. Clin Chem 49:32–40. doi:10.1373/49.1.32 CrossRefPubMed

20.

Ferro V, Dredge K, Liu L et al (2007) PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 33:557–568. doi:10.1055/s-2007-982088 CrossRefPubMed

21.

Ebos JML, Lee CR, Cruz-Munoz W et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232–239. doi:10.1016/j.ccr.2009.01.021 CrossRefPubMed

22.

Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231. doi:10.1016/j.ccr.2009.01.027 CrossRefPubMed

Title: The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
Authors: K. Dredge
E. Hammond
K. Davis
C. P. Li
L. Liu
K. Johnstone
P. Handley
N. Wimmer
T. J. Gonda
A. Gautam
V. Ferro
I. Bytheway
Publication date: 01-06-2010
Publisher: Springer US
Published in: Investigational New Drugs / Issue 3/2010
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-009-9245-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 3/2010

Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer

Chemopreventive efficacy of gallic acid, an antioxidant and anticarcinogenic polyphenol, against 1,2-dimethyl hydrazine induced rat colon carcinogenesis

FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer

Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent

Regulation of cell growth through cell cycle arrest and apoptosis in HPV 16 positive human cervical cancer cells by tea polyphenols

Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants

Keynote webinar | Spotlight on antibody–drug conjugates in cancer